Conference Correspondent

Health-Related Quality of Life in Patients with Metastatic Breast Cancer and Brain Metastases Treated with Tucatinib in Combination with Trastuzumab plus Capecitabine

SABCS 2020 Highlights

Conference Correspondent

NALA Phase 3 Trial Outcomes in Patients Treated with Neratinib or Lapatinib

SABCS 2020 Highlights

Conference Correspondent

HER2CLIMB-02: A Randomized, Double-Blind, Phase 3 Study of Tucatinib with T-DM1 for the Treatment of Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer

SABCS 2020 Highlights

Conference Correspondent

Final Overall Survival Analysis from the Randomized Phase 3 ExteNET Trial of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer

SABCS 2020 Highlights

Conference Correspondent

Hormone Receptor Status Is Not a Factor in the HER2CLIMB Study of Tucatinib Combination Treatment for Patients with HER2-Positive Metastatic Breast Cancer

SABCS 2020 Highlights

Conference Correspondent

Comparison of ARX788 and Lapatinib/Capecitabine in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer

SABCS 2020 Highlights

Conference Correspondent

Efficacy, Safety, and Tolerability of Tucatinib in Combination with Letrozole and Palbociclib in Patients with HR-Positive, HER2-Positive Metastatic Breast Cancer

SABCS 2020 Highlights

Conference Correspondent

Use of Circulating Tumor Cells to Guide Treatment with HER2 Therapy

SABCS 2020 Highlights

Conference Correspondent

Real-World Analysis of Outcomes in Older Women with HER2-Positive Advanced Breast Cancer

SABCS 2020 Highlights

Conference Correspondent

Effect of Brain Metastases in Real-World Treatment Patterns and Healthcare Resource Utilization Among HER2-Positive Metastatic Breast Cancer Patients

SABCS 2020 Highlights

Conference Correspondent

Page 3 of 31

1
2
3
4
5
6
7
8
9
10

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

TON Print Edition

TON Weekly e‑Newsletter

I have reviewed and consent to the terms of TON's Privacy Policy, and TON has my permission to retain my information in its database, and to forward pertinent communications to me.